September 10, 2007
Zeria Pharmaceutical announced on August 28 that it has licensed TM-411 (tamibarotene) from TMRC Co., Ltd., a CRO specializing in oncology which also develops its own compounds as anticancer drugs. Zeria will jointly develop TM-411 with TMRC as a drug...read more